Role of monoclonal antibody drugs in the treatment of COVID-19

Table 1 Randomized clinical trials ongoing on promising inflammatory strategy

Target	Drug type	Drugs
IL 6 signaling	Anti-IL 6	Clazakizumab, Siltuximab
	Anti-IL6 receptor	Sarilumab, Tocilizumab
IL 1 signaling	Anti-IL1β	Canakinumab
	Anti-IL1 repector	Anakinra
JAK-STAT signaling	JAK1/JAK2 inhibitors	Baricitinib, Ruxolitinib
	JAK1/JAK3 inhibitors	Tofacitinib

JAK-STAT: The Janus kinase/signal transducer and activator of tran-ions; IL: Interleukin.

Table 2 Registered randomized clinical trials (source: Clinicaltrials.gov)

Target	Drugs	Clinical trial
IL 6 signaling	Clazakizumab	NCT04348500, NCT04363502, NCT04343989
	Siltuximab	NCT04329650, NCT04322188, NCT04330638
	Sarilumab	NCT04359901, NCT04324073, NCT04357808, NCT04315298, NCT04327388, NCT04345289, NCT04380519, NCT04322773
	Tocilizumab	NCT04317092, NCT04435717, NCT04331795, NCT04412772, NCT04377750, NCT04332094, NCT04377659, NCT04346355, NCT04335071, NCT04403685, NCT04372186, NCT04356937, NCT04320615, NCT04363736, NCT04332913, NCT04363853, NCT04306705, NCT04370834, NCT04339712, NCT04315480, NCT04330638, NCT04322773
IL 1 signaling	Anakinra	NCT04362943, NCT04364009, NCT04324021, NCT04357366, NCT04339712, NCT04330638
	Canakinumab	NCT04362813, NCT04365153
JAK-STAT signaling	Baricitinib	NCT04358614, NCT04373044, NCT04390464, NCT04362943, NCT04401579, NCT04346147, NCT04321993, NCT04345289
	Ruxolitinib	NCT04377620, NCT04362137, NCT04334044, NCT04338958, NCT04403243, NCT04348695
	Tofacitinib	NCT04332042

JAK-STAT: The Janus kinase/signal transducer and activator of tran-ions; IL: Interleukin.